<DOC>
	<DOCNO>NCT00481871</DOCNO>
	<brief_summary>This study patient lymphoproliferative malignancy progress receive previous treatment ( relapse ) longer respond treatment ( refractory ) . To study , patient must certain type Hodgkin 's lymphoma ( HL ) , peripheral T-cell lymphoma ( PTCL ) , B-cell lymphoma , include Waldenstrom 's macroglobulinemia . This study do find doses combination pralatrexate gemcitabine vitamin B12 folic acid safely give patient type lymphoma explore effectiveness treatment .</brief_summary>
	<brief_title>Study Pralatrexate &amp; Gemcitabine With B12 &amp; Folic Acid Treat Relapsed/Refractory Lymphoproliferative Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Phase 1 : Histologically/cytologically confirm lymphoproliferative malignancy . Patients Hodgkin lymphoma ( HL ) nonHL eligible , exception per exclusion criterion . Phase 2a : Histologically/cytologically confirm HL , peripheral Tcell lymphoma ( PTCL ) , Bcell lymphoma include Waldenström 's macroglobulinemia , exception per exclusion criterion . Progression disease ( PD ) least 1 prior treatment ( number prior therapy allow ) . PD last prior treatment recover toxic effect prior therapy . Patients treat FDAapproved monoclonal antibody therapy may enrol time therapy PD . PTCL patient must receive singleagent pralatrexate prior therapy . Eastern Cooperative Oncology Group performance status ≤ 2 . Adequate blood , liver kidney function per laboratory test . Has take 1 mg daily oral folic acid least 7 day prior plan start pralatrexate receive 1 mg vitamin B12 intramuscularly within 10 week plan start pralatrexate . Females childbearing potential must practice medically acceptable contraceptive regimen first dose least 30 day last dose pralatrexate negative serum pregnancy test within 14 day prior first day study treatment . Postmenopausal ( define great 12 month since last menses ) surgically sterilize female require test . Males surgically sterile must practice medically acceptable contraceptive regimen first dose least 90 day last dose pralatrexate . Give write informed consent . Phase 1 1 . Bcell : lymphoplasmacytic lymphoma ( ± Waldenström 's macroglobulinemia ) ; plasma cell myeloma/plasmacytoma ; hairy cell leukemia . Phase 2a 1 . PTCL : precursor T/Natural Killer ( NK ) neoplasms , exception blastic NK lymphoma ; Tcell prolymphocytic leukemia ; Tcell large granular lymphocytic leukemia ; mycosis fungoides ( MF ) , except transform MF ; Sézary syndrome ; primary cutaneous CD30+ disorder : Anaplastic large cell lymphoma lymphomatoid papulosis . 2 . Bcell : plasma cell myeloma/plasmacytoma ; hairy cell leukemia . Relapsed HL diffuse large Bcell lymphoma patient candidate high dose therapy autologous stem cell transplantation ( SCT ) standard curative option . Active concurrent malignancy ( except non melanoma skin cancer carcinoma situ cervix ) . If history prior malignancy , must disease free least 5 year . Congestive heart failure Class III/IV . Uncontrolled hypertension . Human immunodeficiency virus ( HIV ) positive diagnosis CD4 le 100 detectable viral load within past 3 month receive antiretroviral therapy . Hepatitis B C virus detectable viral load immunological evidence chronic active disease receiving/requiring antiviral therapy . Central nervous system disease . Undergone allogeneic SCT . Patients disease refractory peripheral blood SCT , relapse less 100 day since autologous peripheral blood SCT . Active uncontrolled infection , underlie medical condition include unstable heart disease , serious illness impair ability receive protocol treatment . Major surgery within 2 week plan start treatment . Receipt conventional chemotherapy radiation therapy ( encompass great 10 % bone marrow ) within 4 week ( 6 week nitrosoureas mitomycin C ) prior study treatment plan use study . Receipt systemic corticosteroid within 7 day study treatment , unless continuous dose 10 mg/day prednisone least 1 month . Use investigational drug , biologics , device within 4 week prior study treatment plan use study . Received monoclonal antibody within 3 month without evidence PD . Previous exposure pralatrexate and/or gemcitabine discontinue due treatmentrelated toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Lymphoproliferative malignancy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin 's lymphoma ( HL )</keyword>
	<keyword>Non-Hodgkin 's lymphoma ( NHL )</keyword>
	<keyword>PTCL</keyword>
	<keyword>T/NK-cell leukemia/lymphoma</keyword>
	<keyword>T-cell lymphoma/leukemia ( HTLV 1+ )</keyword>
	<keyword>Angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>Blastic NK lymphoma</keyword>
	<keyword>Anaplastic large cell lymphoma</keyword>
	<keyword>T/NK-cell lymphoma</keyword>
	<keyword>Enteropathy-type intestinal lymphoma</keyword>
	<keyword>Hepatosplenic T-cell lymphoma</keyword>
	<keyword>Extranodal peripheral T/NK-cell lymphoma</keyword>
	<keyword>Subcutaneous panniculitis T-cell lymphoma</keyword>
	<keyword>Transformed mycosis fungoides</keyword>
	<keyword>PDX</keyword>
	<keyword>Pralatrexate</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Vitamin B12</keyword>
	<keyword>Folic acid</keyword>
</DOC>